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Background: Tobacco use is a complex, multistage behaviour. The particular stages of this behaviour, including
nicotine dependence (ND), are influenced by both genetics and the environment. Surveys on factors influencing
tobacco use and ND, conducted in ethnically homogenous populations, can provide results less influenced by
genetic and cultural heterogeneity. We aimed to assess ND in a sample of current smokers, derived from the
geographically and culturally isolated population of Kashubians from North Poland, and evaluate its potential
association with age, sex, and self-reported comorbidities. In addition, we attempted to replicate - for the first time
in this population - previous findings on the association between ND and several variants within the CHRNA5A3-A5-B4
nicotine receptor subunit gene cluster.
Methods: The study sample consisted of 969 unrelated subjects who were all current smokers. ND was evaluated
using four measures: the Fagerstrom Test for Nicotine Dependence (FTND), the Heavy Smoking Index (HSI), the
number of cigarettes per day (CPD) and the time to first cigarette after waking (TTF). All subjects underwent
genotyping for CHRNA5 rs16969968, CHRNA3 rs578776, and CHRNB4 rs12914008 variants. Multivariate regression
analysis was used for the assessment of the studied correlations. A significance level of 0.05 with the Bonferroni
correction for multiple testing was set for a type 1 error in the analyses.
Results: The mean CPD, FTND and HSI scores in the study sample were 17.3 ± 7.7, 3.9 ± 2.3 and 2.6 ± 1.5,
respectively. No association between ND defined by FTND, HSI or TTF and age was found. In turn, heavy smoking
was significantly associated with older age (odds ratio (OR) = 1.72, 95% confidence interval (CI): 1.14-2.59, p = 0.009),
and men were more likely than women to be heavy smokers (OR = 1.70, 95% CI: 1.09-2.65, p = 0.018). Chronic
comorbidity did not significantly influence ND. An analysis of association of studied polymorphisms with ND showed
a borderline association of rs16969968 with CPD (OR = 1.63, 95% CI: 1.09–2.45, p = 0.017).
Conclusion: Our study showed a low to moderate level of ND in the Kashubians, influenced by age, sex, as well as the
CHRNA5 rs16969968 variant.
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Tobacco use is one of the most dangerous habits, and as
it is widespread across the world, killed almost 6 million
people in 2011 [1]. Unfortunately, smoking rates are in-
creasing in some developing countries, and still remain
high in many developed countries despite heightened
public awareness of the health risks and public health* Correspondence: asieminska@gumed.edu.pl
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unless otherwise stated.efforts that have been made to reduce cigarette consump-
tion. According to the estimates of the World Health
Organization, if current trends continue, by the year 2030,
eight million people will die annually from tobacco smok-
ing, making this habit the single largest cause of mortality
worldwide [1]. However, the premature deaths and signifi-
cant morbidity associated with smoking can be entirely
preventable; therefore, more measures must be under-
taken worldwide to stop the tobacco epidemic. Studies
identifying the factors influencing tobacco dependenceral. This is an Open Access article distributed under the terms of the Creative
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tinuation will likely play a significant role in achieving
this goal [2].
Tobacco use is a complex, multistage behaviour that
includes initiation, experimentation, regular use, depend-
ence, cessation, and relapse [3,4]. This behaviour is influ-
enced by both genetics and the environment [5]. Classical
genetic twin studies, allelic association studies on candi-
date genes, and more recently, genome wide association
studies (GWAS), have yielded strong evidence on the
substantial role of genetics in phenotypes displayed at
every stage of this behaviour, including nicotine depend-
ence (ND) [6-13]. In the last decade, the genetic region
that may be involved in the pathogenesis of ND was
identified to be present within chromosome 15 [12,13].
This genome region comprises a cluster of genes encod-
ing the CHRNA5, CHRNA3, and CHRNB4 subunits of
the neuronal nicotinic acetylcholine receptor (nAChR)
[12,13]. nAChRs in the central nervous system largely
mediate the effects of nicotine, the primary substance
responsible for the addiction that contributes to main-
taining tobacco use [14]. After binding to nAChRs,
nicotine stimulates dopamine release in the striatum, a
region of the brain that is involved in the reward path-
way and is crucial to the development of substance de-
pendence [15-17]. Several genome-wide association and
candidate genes studies have provided further evidence
supporting the relationship of different loci within this
gene cluster with various ND phenotypes the number of
cigarettes smoked daily (CPD), the Fagerström Test for
Nicotine Dependence (FTND) [18] score, and FTND-
derived measures such as the Heavy Smoking Index (HSI)
[19] and the Time to First Cigarette (TFF) or the age at
starting daily smoking [13,20-25].
Most frequently, a significant association of ND with
the rs16969968-tagged locus, or single nucleotide poly-
morphisms (SNPs) that are highly correlated with it
(r2 ≥ 0.8), was found in numerous independent studies in
subjects of Caucasian origin [20-22,26]. Owing to this
strong evidence of the contribution of rs16969968 to
ND, especially when defined by CPD, this association
seems to be stably established [27,28]. In addition, several
distinct loci that have low linkage disequilibrium (LD)
with rs16969968, including rs578776 and rs12914008,
were found to influence nicotine-related phenotypes
[12,13,20,22-24,29].
The environment is the second component influencing
tobacco use and ND phenotypes. The most important
environmental factors include socio-cultural influences,
which are specific to different ethnic or geographical
populations [30,31]. Therefore, there is a considerable
cultural variation in tobacco use worldwide. In addition,
the influence of ethnic and cultural factors on tobacco
use phenotypes can be modified by genetic factors, whichcan exert different effects across different populations
because SNP allele frequencies and their association
with ND can differ between various ethnic or geographic
populations and subpopulations owing to variations in the
extent of LD in these different groups. The effects of genes
that contribute to tobacco use and ND might be enhanced
in isolated, genetically homogeneous populations that are
characterized by limited allelic diversity.
Kashubians are a relatively small population that
inhabits Kashubia, North Poland; a region in Poland’s
Pomeranian Province. Currently, the number of indigen-
ous Kashubians living in this region is estimated at nearly
230,000 [32]. Kashubians are considered to be an isolated
population, although the genetic structure of this popula-
tion has not yet been exhaustively studied. The assumed
isolation of Kashubians is based mainly on cultural and
linguistic reasons, as well as on the geographical location
of Kashubia in the outskirts of North Poland. However, a
study of the history of Kashubians across centuries sug-
gested that this population might instead be classified as
secondarily isolated, i.e., isolated after being detached from
a large population, which then slowly expanded with very
little recruitment from outside the group. Kashubians are
first mentioned in historical records from the middle of the
thirteenth century; however, the age of this population is
not precisely known. Nevertheless, several lines of evidence
in the Kashubian population conform to the criteria of an
isolated population: an old settlement, high rates of en-
dogamy with consanguineous marriages between distant
relatives, and slow population expansion with negligible
immigration, accompanied by the conservation of a strong
socio-cultural identity, including distinct dialect and trad-
itional customs.
In addition to genetic and environmental factors, differ-
ent smoker’s individual factors, including comorbidities,
can contribute to tobacco use and ND [5]. Therefore, the
aim of our study was to assess ND in a convenience
sample of current smokers of Kashubian descent, and to
correlate results with the basic demographic variables and
concomitant chronic conditions. In addition, we attempted
to replicate - for the first time in this population - previous
findings on the association between several variants within
the CHRNA5A3-A5-B4 gene cluster and ND.
Methods
Ethics statement
The institutional research ethics committee at the Medical
University of Gdansk approved all study procedures, and
all subjects provided written, informed consent prior to
participation in the study.
The study sample
The convenience sample was selected from both the
consecutive outpatients attending several health centres
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in Kashubia. Participants were adult, non-related, cur-
rent cigarette smokers, who self-identified as being of
Kashubian descent. A current smoker was defined as
someone who self-reported smoking cigarettes daily or oc-
casionally for at least 1 year at the moment of recruitment
to the study. The recruitment of eligible subjects of
Kashubian origin was conducted by nurses, who are
skilled in questionnaire face-to-face interviews for collect-
ing demographic, genealogical, and smoking habit data. In
addition, information on the presence of any chronic dis-
eases, including psychiatric disorders, was obtained from
participants by self-reporting. The Kashubian origin of par-
ticipants was confirmed by being born into a Kashubian
family (i.e., both a mother and a father, as well as four
grandparents were Kashubian) and by a command of the
Kashubian language. In order to exclude first-degree rela-
tives, every consecutive participant was asked to list their
living parents, adult siblings, and offspring in the ques-
tionnaire. The information of all of these relatives was
then collected in a separate database. Upon recruitment of
each new subject, this database was consulted to check
whether the new potential recruit had already been recor-
ded as a first-degree relative of any other previously
recruited subject. If two subjects were found to be first-
degree relatives, only the younger subject, preferentially
without any self-reported chronic disease, was included in
the study.
Initially, 1110 subjects who were current smokers and
self-identifying as being of Kashubian descent were re-
cruited into the study. Finally, after excluding 141 (12.7%)
subjects who did not fulfill the criteria of definite
Kashubian origin or appeared to be first-degree relatives
of any other participant, the study population comprised
969 subjects: 748 (78%) subjects who had been recruited
in health centres and 221 (23%) blood donors.
Nicotine dependence measures
ND was assessed by the Fagerström Test for Nicotine
Dependence (FTND), the measure that conceptualized
nicotine dependence as a syndrome characterized by
physiological, cognitive, and behavioral symptoms. The
FTND has six items, and therefore, the scores are com-
monly treated as continuous variables with the depend-
ence status varying in degree.
The Heaviness of Smoking Index (HSI), which is
derived, similarly to FTND, from the Fagerström Tolerance
Questionnaire [33] was also recorded in each participant.
HSI is considered a brief version of the FTQ or FTND,
which retains their two main items: the number of ciga-
rettes smoked per day (CPD) and the time to first cigarette
after waking (TTF). The values for HSI as the sum of these
two categorical measures range from 0 to 6, which corres-
pond to the following for CPD: 0: 0–10 CPD; 1: 11–20CPD; 2: 21–30 CPD; and 3: 31+ CPD. The HSI scores for
TTF are: 0: 61+ min; 1: 31–60 min; 2: 6–30 min; and 3: up
to 5 min.
Heavy smokers were defined as those who smoked
more than 20 cigarettes daily, and chippers were defined
as smokers who smoked occasionally or up to five ciga-
rettes daily [34].
Sample collection procedures and genotyping
Upon recruitment of each subject, an 8-mL venous
blood sample was collected into heparinized tubes. Sam-
ples were frozen and stored at −80°C until required for
molecular genotypic analyses. Based on previous find-
ings, three SNPs for ND were selected for genotyping:
rs16969968 in CHRNA5, rs578776 in CHRNA3, and
rs12914008 in CHRNB4 [12,13,20-29].
Genomic DNA was extracted from lymphocytes and
used as a template for real-time polymerase chain reac-
tion (PCR). DNA isolation was performed with the use
of the Micro Blood Gravity kit (A&A Biotechnology),
according to the manufacturer protocol. The DNA sam-
ples were then diluted 10 times in 10 mM Tris buffer,
pH 8.0, and stored at 4°C. PCR amplification was carried
out in a total volume of 30 μL by using 5 μL of the di-
luted DNA and Real Time 2x PCR Mix SYBR A or Real
Time 2x PCR Mix EX SYBR A (A&A Biotechnology).
PCR was carried out in the iCycler system (Bio-Rad)
using SYBR Green as a fluorochrome. Cycling was car-
ried out with an initial denaturation at 95°C for 3 min
followed by 40 cycles of 95°C for 15 s and 62–68°C for
1 min. The amplified DNA fragments were 130–350 bp.
Melt curves were generated by holding the PCR plate at
95°C for 1 min followed by 55°C for 10 s. The tempe-
rature was then increased every 0.5°C to the final tempe-
rature of 95°C using step fluorescence acquisition. Melt
curve profiles were assessed and analyzed using iCycler
software. To validate the method, selected samples were
resolved on 2% agarose gel.
Statistical analyses
The Hardy-Weinberg Equilibrium (HWE) test was
performed with Haploview software (version 4.2) [35].
The chi-squared (χ2) test with continuity correction
whenever appropriate was used for group comparisons of
allele and genotype frequencies.
Multivariate logistic regression analysis was applied
with the use of STATISTICA 10.0 software (StaSoft Inc.;
USA) to estimate correlations between chosen polymor-
phisms, demographic variables, and comorbidities, and
FTND, HSI, CPD and TTF. Age was dichotomized with
the use of a cut-off point of 45 years, since the median
value of age in the sample was 44.2 years. FTND, HSI,
CPD and TTF were incorporated into the analysis as di-
chotomous traits with FTND 4+, HSI 3+, CPD 20+ and
Table 1 A smoking profile and comorbidities in the
Kashubian sample of current smokers
Characteristics Values: N (%),
Mean ± SD
Males 608 (62.7)
Age (years) 44.2 ± 14.2
Age category:
<30 yrs 194 (20.0)
30-45 yrs. 283 (29.2)
46-60 yrs. 384 (39.6)
>60 yrs. 108 (11.1)
Daily smokers 902 (93.1)
Tobacco chippers 107 (11.0)
Heavy smokers 114 (11.8)
Age at starting smoking (years) 19.1 ± 4.2
Smokers who started smoking in the age ≤16 yrs 206 (21.3)
Duration of smoking; years 23.0 ± 13.1
No. of cigarettes smoked daily 17.3 ± 7.7
FTND* 3.9 ± 2.3
HSI* 2.6 ± 1.5
TFC ≤5 min 230 (25.5)
Subjects with any chronic comorbidities 285 (29.4)
Respiratory diseases 67 (6.9)
Cardiovascular diseases 148 (15.3)
Gastrointestinal tract diseases 20 (2.1)
Degenerative spine and/or joint disease 40 (4.1)
Endocrine disease 59 (6.1)
Psychiatric disorders 12 (1.2)
Other 40 (4.1)
Subjects with a history of neoplasm 12 (1.2)
*FTND and HSI scores were 0 in the occasional smokers.
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chosen for differentiating smokers with higher level of
ND from those with lower level of ND. Because smoking
quantity as a proxy phenotype for ND has been recog-
nized to have the strongest association with SNPs at
CHRNA5-CHRNA3-CHRNB4 nicotinic receptor subunit
gene cluster, the correlations between rs16969968,
rs578776 and rs12914008 and CPD were additionally
assessed.
The results were presented as odds ratios (ODs) with
their 95% confidence intervals (95% CI). A significance
level of 0.05 with was set for a type 1 error in all analyses.
The Bonferroni correction procedure for multiple testing
was used whenever appropriate.
Results
The study sample consisted of 969 current smokers: 361
women aged 20–82 years (mean age 46.6 ± 11.9 years)
and 608 males aged 19–85 years (mean age 42.7 ±
15.2 years). The mean CPD, FTND and HSI scores in the
study sample were 17.3 ± 7.7, 3.9 ± 2.3 and 2.6 ± 1.5, re-
spectively. Women smoked on average 14.6 ± 7.8 ciga-
rettes per day, and men smoked 16.9 ± 8.9. One hundred
and fourteen (11.8%) subjects met the definition for heavy
smokers, and 108 (11%) for chippers. Among 285 subjects
who self-reported any concomitant chronic diseases, the
most prevalent were cardiovascular diseases, followed by
diseases of respiratory system. There were 12 (1.2%) sub-
jects with concomitant psychiatric disorders and 12 (1.2%)
subjects with a history of neoplasm. The demographic
data, comorbidities, and smoking profile of the study sam-
ple are shown in Table 1.
All subjects successfully underwent genotyping. The
distributions of genotypes for rs16969968, rs578776, and
rs12914008 did not deviate to any appreciable extent
from expectations predicted by the Hardy-Weinberg
equilibrium (p = 0.66, p = 0.68, and p = 0.66, respectively).
The frequencies of alleles and genotypes for the three
studied SNPs found in the Kashubian sample did not dif-
fer significantly from those downloaded from the HapMap
CEU reference population (www.hapmap.org), except for
the variant allele A of rs16969968. This variant was signifi-
cantly less frequent in the Kashubian sample (p = 0.02).
The frequencies of alleles of rs16969968 in CHRNA5,
rs578776 in CHRNA3, and rs12914008 in CHRNB4, and
the frequencies of genotypes found in the sample are pro-
vided in Table 2.
In multivariate logistic regression analysis, there were
no association between ND defined by FTND, HSI or
TTF and age (Table 3). In turn, heavy smoking was sig-
nificantly associated with older age (OR = 1.72, 95% CI:
1.14-2.59, p = 0.009), and men were more likely than
women to be heavy smokers (OR = 1.70, 95% CI: 1.09-
2.65, p = 0.018) (Table 3). Women were more likely thanmen to be physically non-dependent to nicotine, i.e.,
smoked up to 5 cigarettes daily or smoked occasionally
(OR = 1.87, 95% CI: 1.25-2.82; p = 0.0025). However,
having been a chipper was not associated with age
(OR = 0.87, 95% CI: 0.58-1.31; p = 0.52).
Health status as an independent variable dichotomized
into the presence and absence of any chronic disease did
not significantly influence ND defined by FTND, CPD,
HSI, and TTF (Table 3).
No association was also found between particular cat-
egories of concomitant chronic diseases, i.e., respiratory
diseases, cardiovascular diseases, or a history of neo-
plasms with four studied phenotypes of ND (data not
shown), except for psychiatric disorders that were sig-
nificantly associated with the higher OR for TTF ≤5 min
(OR = 4.16, 95% CI: 1.30-13.30, p = 0.016). The risk of
smoking the first cigarette up to 5 minutes after wak-
ening, after adjusting for age and psychiatric disorders,
Table 2 Frequencies of alleles and genotypes in
rs16969968-, rs578776-, and rs12914008-tagging loci in











A 30.6 38.5 0.02
G 69.4 61.5
AA 9.7 15.9 0.04
AG 41.8 45.1 0.50
GG 48.5 38.9 0.05
rs578776
(CHRNA3)
C 72.1 75.2 0.33
T 27.9 24.8
CC 51.7 56.6 0.32
CT 40.9 37.2 0.45
TT 7.4 6.2 0.63
rs12914008
(CHRNB4)
A 4.6 3.3/1.7 0.68
G 95.4 96.7
AA 0.3 0 0.42
AG 8.6 6.7 0.78
GG 91.1 93.3 0.72
*HapMap Data Release 27 Phase II + III, February 2009.
**Global MAF in 1000 Genome Phase1 genotype data from 1094 worldwide
individuals released in the May 2011 dataset.
Values in boldface denote a significant association.
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95% CI: 0.98-1.80, p = 0.07).
The risk of starting smoking up to 16 years of age was
significantly lower in women (OR after adjusting for age
and psychiatric disorders = 0.53; 95% CI: 0.37-0.74, p =
0.0002).
Logistic regression results for the associations between
ND defined by FTND, CPD, HSI or TTF and selected
genotype variables are presented in Table 4. Risk allele at
rs16969968 was found to be significantly associated with
smoking more than 20 CPD. However, the p-value reached
only a borderline significance after Bonferroni correction
for the multiple testing.
Discussion
In general, a low to moderate level of ND defined by
FTND and HSI scores was found in the studied sample
of Kashubians. In addition, in comparison to data ob-
tained from the Global Adult Tobacco Survey (GATS)
on tobacco use in 16 low-income and middle-income
countries including Poland, Kashubians smoked on aver-
age fewer cigarettes daily (females and males, 14.6 and
16.9, respectively) than smokers in the general Polishpopulation (females and males, 15.5 and 18.3, respect-
ively) [36].
The risk of heavy smoking was significantly higher in
smokers aged 45 years and older and males were more
likely to be heavy smokers. Similar to other reports,
women were more likely than men to be chippers, i.e.,
smokers physically non-dependent to nicotine. However,
they were more likely, although not significantly, to
report behaviour indicating physiological addiction (time
to first cigarette) [37-39]. In concordance with reports
from different countries and populations, they also started
smoking later than men [39-41].
Our study showed that coexistence of chronic disease/
diseases did not influence ND. Similarly, an analysis of
the association between the coexistence of particular
categories of comorbidities and ND did not show any
significance, except for mental illnesses which are rec-
ognized as a risk for tobacco use and ND [42]. Even
respiratory and cardiovascular system diseases that are
commonly known to be related to or that are aggravated
by cigarette smoking did not have any significant impact
on ND. The only significant association that was found in
subjects with psychiatric disorders related to an increased
risk for TTF <5 min. Among those subjects, women were
more likely than men to smoke their first cigarette within
5 min of wakening. In turn, we did not find an association
between psychiatric disorders and CPD 20+, although
there is evidence in the literature indicating this relation-
ship [43-45]. Non-replication of the association could have
been caused by several different factors. It has been sug-
gested that heavy smoking and the urgency to smoke,
which corresponds to TTF, may not share the same aeti-
ology [46,47]; this may be one of the factors resulting in
the non-replication.
The influence of CHRNA5 rs16969968 on CPD has
been firmly established [27,28]. The results of our study
are in agreement with existing evidence that the CHRNA5
rs16969968 polymorphism is associated with CPD as a
proxy for ND. The OR for heavy smoking was 1.63 (95%
CI: 1.09-2.45; p = 0.017) in carriers of the rare variant of
this polymorphism, i.e., subjects with the AA or AG geno-
type, compared to non-carriers. However, after applying
Bonferroni correction for multiple testing, this association
appeared to be only borderline significant. The relatively
small sample size was among the factors that may have
hindered demonstrating a robust association. In addition,
the lower minor allele frequency (MAF) of rs16969968 in
the Kashubian population (30.6%) than that in other pop-
ulations of Caucasian origin might have diminished the
statistical power of our analysis. For instance, the MAF
was 38.5% in the CEU population (HapMap Data Rel 27
Phase II + III, Feb. 2009) and 35.0% in the European-
American sample analysed in the study by Saccone et al.
[23]. If that was the case, the low MAF (4.6%) of another
Table 3 Age, sex and chronic comorbidity associations with selected nicotine dependence measures
Variables FTND No. of subjects OR (95% CI)
p-value
CPD* No. of subjects OR (95% CI)
p-value
HSI No. of subjects OR (95% CI)
p-value
TTF No. of subjects OR (95% CI)
p-value<4 ≥4 ≤20 >20 <3 ≥3 ≤5 min >5 min
Females 170 191 1 293 31 1 151 173 1 100 261 1
Males 270 338 1.17 (0.90-1.53) 0.24 495 83 1.70 (1.09-2.65) 0.018 284 294 1.04 (0.80-1.37) 0.75 130 478 0.74 (0.55-1.01) 0.05
Age <45 years 233 244 1 396 44 1 217 223 1 102 375 1
Age ≥45 years 207 285 1.25 (0.95-1.64) 0.10 392 70 1.72 (1.14-2.59) 0.009 218 244 1.07 (0.80-1.42) 0.64 128 364 1.16 (0.84-1.60) 0.35
Chronic
comorbidity -
324 360 1 560 77 1 363 321 1 152 532 1
Chronic
comorbidity +
116 169 1.22 (0.91-1.65)0.18 228 37 1.00 (0.92-1.09) 0.97 139 146 1.17 (0.87-1.57) 0.31 78 207 1.22 (0.87-1.71) 0.24
*Only daily smokers.
Values in boldface denote a suggestive association and values in bold italics denote the significant association when applying Bonferroni correction for multiple testing (significance level: p = 0.0125).














Table 4 Logistic regression results for the association between smoking more than 20 cigarettes per day and selected polymorphisms
















<4 ≥4 ≤20 >20 <3 ≥3 ≤5 min >5 min
rs16969968
at CHRNA5/
GG 218 252 1 397 44 1 251 219 1 103 367 1
AA + AG 222 277 1.08 (0.83-1.40) 0.56 391 70 1.63 (1.09-2.45) 0.017** 251 248 1.13 (0.88-1.46) 0.33 127 372 1.22 (0.91-1.65) 0.19
rs578776
at CHRNA3/
CC 232 269 1 403 62 1 264 237 1 119 382 1
TT + TC 208 260 1.09 (0.84-1.41) 0.52 385 52 0.89 (0.60-1.30) 0.56 238 230 1.08 (0.84-1.39) 0.55 111 357 0.99 (0.73-1.33) 0.94
rs12914008
at CHRNB4/
GG 398 485 1 717 105 1 455 428 1 209 674 1
AA + AG 42 44 0.86 (0.55-1.35) 0.52 71 9 0.87 (0.42-1.80) `0.70 47 39 0.88 (0.57-1.38) `0.58 21 65 1.04 (0.61-1.77) 0.90
*Only daily smokers.
**A rounded down p-value. The exact p-value is 0.01756.
The values in boldface denote the suggestive association when applying Bonferroni correction procedure for multiple testing (significance level: p = 0.017).
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in the Kashubian population, may have required a much
larger population sample to find any association between
that polymorphism and CPD. We decided to study this
locus for two reasons. Firstly, the frequencies of minor
and major alleles in CHRNB4 rs12914008 in Kashubians
had not been studied before. Secondly, this locus seemed
intriguing because evidence of the involvement of this
locus in ND had not yet been clearly established. Initially,
CHRNB4 rs12914008 was found to exert a protective ef-
fect against ND via its rare minor allele, with an estimated
MAF of 4.5% [23]. However, another meta-analysis includ-
ing 34 datasets from subjects of European ancestry did
not show such effects of this locus on ND phenotypic sta-
tus, defined by a dichotomous CPD measure [24]. The as-
sociation between this variant and multi-item measures of
ND has not been widely studied to date. To the best of
our knowledge, only Sarginson et al. [25] tested the associ-
ation between rs12914008 and the modified FTQ, demon-
strating a negative result. Therefore, we included
rs12914008 in our analysis of ND in Kashubians to inves-
tigate the potential role of this polymorphism in ND.
In spite of the evidence that the minor allele T of
CHRNA3 rs578776 is associated with a decreased CPD
value, i.e., it confers protection against ND [23,24,48], we
did not replicate such an association in the study group.
Once again, this may be attributed to an insufficient sam-
ple size and a reduced statistical power.
In our study, four measures of ND were applied,
including FTND, CPD, TTF, and HSI, to investigate which
among them, if any, were most influenced by age, sex, co-
morbidities and the chosen polymorphisms. The FTND
has been accepted as a standard measure in both clinical
and research settings. This measure encompasses both
physiological and psychological (cognitive and behav-
ioural) aspects of dependence, although some evidence
has suggested that it has poor psychometric properties
and does not cover all important aspects of dependence,
such as cravings, compulsion to smoke, nicotine with-
drawal symptoms, behavioural saliency, and behavioural
atomaticity, which are often regarded as the core con-
struct of ND [49-52]. Other studies have demonstrated
that the indices of psychological dependence could ex-
plain approximately 20% of the variance in FTND scores
[53]. More recently, it was found that FTND is an in-
strument that primarily taps into behaviours that reflect
how smokers cope with nicotine withdrawal [54]. The
lack of association of FTND with studied demographic
variables as well as chosen polymorphisms may result in
part from these properties of FTND. Finding the associ-
ation between FTND and a given polymorphism can be
especially difficult, since a single SNP may influence a
strictly defined aspect of physiological or psychological
ND [55].Therefore, in addition to FTND, we used two single
FTND-derived items CPD and TTF alone as proxy mea-
sures of ND. We found that heavy smoking, which is a
strong indicator of physiological ND, was significantly
associated with age and marginally associated with sex
and the AA +AG genotype at the CHRNA5 rs16969968
locus. The second item of HSI, TTF, was significantly
associated only with psychiatric disorders. However, be-
cause of the small number of subjects with concomitant
psychiatric disorders this association should be consid-
ered with caution.
Finally, we applied the HSI - a composite of CPD and
TTF - as a measure of ND. Contrary to the FTND, the
HSI emphasizes physiological dependence only, charac-
terized by a smoker’s desire to maintain blood nicotine
levels [19]. Since the average HSI score was 2.6 ± 1.5 in
our sample, we applied a cut-off point of 3 to categorize
smokers as having low/medium or high ND, as opposed
to a cut-off point of 4, which was commonly used in the
literature [56]. However, all studied variables in our ana-
lysis did not influence HSI.
There are several strengths of this study that should
be highlighted. Firstly, we focused on a geographically
and culturally isolated population so that the study sample
was mostly genetically and culturally homogenous. Thus,
we attempted to alleviate potential concerns regarding
population stratification. Secondly, our analyses consid-
ered the possible influence of comorbidities on ND. We
attempted to study which chronic concomitant disease
modified ND traits. Thirdly, since our study group con-
sisted of nonrelated subjects, we attempted to avoid those
who could share common family environmental influ-
ences on ND.
The study also had limitations. Firstly, the study sam-
ple was not representative of the whole population of
Kashubian smokers. In saying this, design of the study
required this for convenience sampling. Therefore,
non-related participants and current smokers were non-
randomly recruited from patients and blood donors
attending chosen medical centres or blood donations
centres. Taking into account the considerable proportion
of subjects with concomitant chronic diseases - many of
which could influence the ND measures - the results of
regression analyses were adjusted for the presence of co-
morbid conditions. Additionally, participants’ self-reports
of their concomitant chronic diseases were not confirmed
by a formal clinical interview or by checking medical
documentation. This may have led to underreporting,
especially in case of psychiatric disorders.
Secondly, only age and sex as basic demographic vari-
ables were included in the multivariate analysis, while fac-
tors known to be strongly correlated with smoking and
ND, such as socioeconomic status or marital status, were
not studied [57]. However, since we aimed to incorporate
Sieminska et al. BMC Public Health  (2015) 15:80 Page 9 of 11three SNPs at the CHRNA5-CHRNA3-CHRNB4 subunit
gene cluster as genetic factors in the regression analysis,
incorporating more socioeconomic variables would have
demanded a significantly larger sample to detect any rele-
vant association after applying Bonferroni correction.
Nevertheless, our sample size and statistical power
appeared to be too small to confirm statistical significance
of the association between the CHRNA5 rs16969968 poly-
morphism and CPD. Small sample size is considered one
of the most common reasons for failure to replicate
reported associations across studies [58]. Since the genetic
background of ND probably requires the contribution of
many genes of small effect, gene-gene interactions as well
as gene-environment interactions should be evaluated to
help explain the risk of developing a trait as complex as
smoking. However, detecting these types of genetic effects
and interactions requires samples of tens to hundreds of
thousands of subjects. On the other hand, Bonferroni cor-
rection is considered a highly conservative method for
multiple statistical comparisons [59] and was possibly too
stringent for our attempts to replicate previously found
robust associations between variants of the CHRNA5-A3-
B4 region and ND.
Another limitation of the study was the self-reporting
of smoking quantity, which was not verified biochemically
by the measurement of nicotine metabolites. Therefore,
one can expect some degree of misreporting of smoking
behaviour by smokers (e.g., reporting that they smoke
fewer cigarettes than they actually do) [60]. Finally, both
the Kashubian ancestry and the lack of first-degree
relatives among participants of the study were based
on self-reports, and were not verified at the genetic
level. Therefore, we could not confirm the genetic homo-
geneity of the studied population or exclude individuals
that were unexpectedly related to each other.
Despite its potential limitations, the present study is
the only available estimate of ND in an ethnically and
culturally homogenous population of Kashubians. We
consider that isolated populations could serve as good
samples for identifying genetic and environmental deter-
minants of tobacco use and ND. Unfortunately, in current
times of increasing cultural and genetic intermixing be-
tween populations, it may be difficult to find an ethnically
and culturally homogenous sample in the future.
Conclusions
To conclude, a low to moderate level of ND was observed
among smokers in the sample of Kashubians. Age and sex
have influence on CPD and it is likely that psychiatric co-
morbidities may influence TTF. Female sex is associated
with a lower risk for starting smoking under the age of
16 years. In addition, the present study confirms that
CHRNA5 rs16969968 may contribute to the complex
biological role of the CHRNA5-A3-B4 gene cluster on therisk of ND, as defined by the number of cigarettes smoked
daily. Efforts to better recognize ND are of great import-
ance so that new approaches can be developed to reduce
tobacco use, especially cigarette smoking. The continued
identification of environmental factors and the search for
genes involved in the development of ND will help in
improving treatment measures for smoking cessation.
Adjustment of treatments to personal environmental de-
terminants and implementation of novel drugs tailored to
personal genetic backgrounds and the stage of an indi-
vidual’s ND may significantly increase the efficacy of
treatment.
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